Related Experiment Video
Updated: Apr 5, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy
Heather A Personett1, Scott L Larson1, Erin N Frazee1,2,3
1Pharmacy Services, Mayo Clinic Hospital, Rochester, Minnesota.
Abstract:
Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein-bound and water-soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram-negative infections. Use of an extended-infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.
Insights
Molecular Adsorbent Recirculating System (MARS) therapy may enhance piperacillin/tazobactam clearance. Extended infusions maintained therapeutic piperacillin serum levels in patients undergoing MARS treatment.
Area of Science:
- Pharmacology
- Nephrology
- Critical Care Medicine
Background:
- The Molecular Adsorbent Recirculating System (MARS) is increasingly used for liver support, removing various molecules from the blood.
- The impact of MARS on drug elimination, particularly antibiotics, is not well understood.
- Suboptimal antibiotic levels can lead to poor patient outcomes in acute care settings.
Observation:
- This study investigated piperacillin/tazobactam clearance in two patients undergoing MARS therapy.
- Piperacillin concentrations were measured within the MARS circuit and in patient serum.
- The study assessed the effectiveness of extended-infusion strategies for maintaining therapeutic drug levels.
Findings:
- Piperacillin concentrations within the MARS circuit indicated enhanced drug elimination.
- Extended-infusion piperacillin/tazobactam (3.375 or 4.5 g every 8 hours) successfully maintained desired serum concentrations.
- Achieved piperacillin levels exceeded the minimum inhibitory concentrations for gram-negative infections.
Implications:
- Successful dosing strategies for piperacillin/tazobactam in patients on MARS therapy were identified.
- The study quantifies the influence of MARS components on piperacillin extraction.
- Findings are crucial for acute care practitioners managing patients requiring antibiotics during liver support therapy.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Drug Elimination by Renal Route: Tubular Secretion
Drug Elimination: Non-Renal Routes
Drug Elimination by Renal Route: Tubular Reabsorption

